Revance Therapeutics reported $72K in Ordinary Share Capital for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ordinary Share Capital Change
Adamas Pharmaceuticals ADMS:US 50K 0
Aerie Pharmaceuticals AERI:US $ 0.05M 0M
ALKERMES ALKS:US $ 1.65M 0.01M
Antares Pharma ATRS:US $ 1.7M 0.01M
Biodelivery Sciences International BDSI:US $ 0.1M 0M
Bristol Myers Squibb BMY:US $ 292M 0M
Cara Therapeutics CARA:US $ 50K 0
Coherus Biosciences CHRS:US $ 0.01M 0M
Eli Lilly And LLY:US $ 598.1M 1.6M
Endo International Ordinary Shares ENDP:US $ 0.07M 0M
Flexion Therapeutics FLXN:US $ 50K 0
Gw Pharmaceuticals GWPH:US $ 0.58M 0.01M
Horizon Pharma HZNP:US $ 0.02M 0M
JAZZ PHA JAZZ:US $ 0.06M 0M
Neurocrine Biosciences NBIX:US $ 0.1M 0M
Pacira Pharmaceuticals PCRX:US $ 0.04M 0M
Procter & Gamble PG:US $ 4009M 0M
Revance Therapeutics RVNC:US $ 0.07M 0M
Supernus Pharmaceuticals SUPN:US $ 0.05M 0M
Teva Pharmaceutical Industries TEVA:US $ 57M 0M
Zogenix ZGNX:US $ 0M 0M